Condition: Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion · Sponsor: Shouyao Holdings (Beijing) Co. LTD
This is an open-label, single-arm, multicenter, dose-escalation and dose-expansion, phase I study to the safety, tolerability, pharmacokinetics, and preliminary efficacy of SY-9453 in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
chen guang wang · 010-8885-8866 · cgwang@centaurusbio.com
Always discuss trial participation with your own doctor first.
| Shanghai East Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07469982